Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-765 in treatment-resistant partial epilepsy
NCT01501383Phase 2Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2011
- Primary completion
- Aug 2013
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of belnacasan in partial epilepsy, sponsored by Vertex Pharmaceuticals. Started Dec 2011; status: terminated.
02
Drugs
belnacasan
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT01501383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01501383.